2022 Year In Review for investor audiences
Regeneron leaders reflect on 2022 accomplishments. Learn more about our approved medicines, including Prescribing Information.
For 35 years, Regeneron has remained steadfast in our mission to use the power of science to repeatedly bring new, life-transforming medicines to patients.
Our products and pipeline are designed to help patients across many disease areas, and we are always looking for ways to accelerate and improve the traditional drug development process through our innovative technologies and ambitious research initiatives.
From conducting one of the world’s largest genetics sequencing efforts, to expanding on our proprietary VelociSuite® technologies, to advancing novel and investigational bispecific antibodies, we are applying our homegrown tools and relentless spirit to discover new targets and potential treatments, advance our clinical studies and help reach people with serious diseases around the world.
BRINGING OUR SCIENCE-LED APPROACH TO
PATIENTS, COMMUNITIES AND SOCIETY
(as of April 2023)
investigational medicines in clinical development
countries with Regeneron clinical trials
Regeneron employees worldwide at year end
countries with Regeneron offices
partnerships with small businesses and diverse suppliers
global and U.S. patient advocacy and professional societies engaged across more than 35 diseases
consecutive years on the Dow Jones Sustainability World Index
of Regeneron-owned sites maintained zero waste-to-landfill
Excludes construction and demolition waste
of single-use latex and nitrile gloves recycled into new items at our Rensselaer site
hours of employee community service through our annual Day for Doing Good
in Regeneron STEM
initiatives since 2020
employee resource groups providing inclusive professional development and leadership opportunities
This Year in Review contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Please see Regeneron’s press release announcing its financial and operating results for the fourth quarter and full year 2022 for important information about Regeneron’s forward‑looking statements.